We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
The alternative CD20 transcript variant is not a surrogate marker for resistance to rituximab in patients with rheumatoid arthritis.
- Authors
Gamonet, Clémentine; Deschamps, Marina; Marion, Sandrine; Herbein, Georges; Chiocchia, Gilles; Auger, Isabelle; Saas, Philippe; Ferrand, Christophe; Toussirot, Eric
- Abstract
The article discusses a study of 23 patients with rheumatoid arthritis (RA) and 20 healthy subjects (HSs) to determine the efficacy of rituximab (RTX) for RA treatment. The study shows that circulating B cells and those present in the synovial tissue from RA patients do not express the d393-cd20 transcript regardless of their response to RTX indicating that the d393-cd30 transcript is a molecular marker of B cell malignancies instead of autoimmune disease.
- Subjects
FRANCE; RITUXIMAB; ACADEMIC medical centers; BIOPSY; BLOOD testing; DRUG resistance; POLYMERASE chain reaction; RESEARCH funding; RHEUMATOID arthritis; REVERSE transcriptase polymerase chain reaction
- Publication
Rheumatology, 2015, Vol 54, Issue 9, p1744
- ISSN
1462-0324
- Publication type
Article
- DOI
10.1093/rheumatology/kev210